Stockscreener 앱 받기
11.98
0.84%
0.10
시간 외 거래:
11.94
-0.04
-0.33%
전일 마감가:
$11.88
열려 있는:
$11.77
하루 거래량:
207.07K
Relative Volume:
0.96
시가총액:
$458.65M
수익:
$25.42M
순이익/손실:
$-143.75M
주가수익비율:
-3.4516
EPS:
-3.4709
순현금흐름:
$-129.55M
1주 성능:
-7.70%
1개월 성능:
+5.00%
6개월 성능:
+121.03%
1년 성능:
+11.44%
1일 변동 폭
$11.23
$12.06
1주일 범위
$11.23
$13.27
52주 변동 폭
$4.93
$13.65
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
11.98 | 454.82M | 25.42M | -143.75M | -129.55M | -3.4709 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-11 | 개시 | Guggenheim | Buy |
| 2026-01-28 | 개시 | Oppenheimer | Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Aug EndMonth: How does Entrada Therapeutics Inc compare to its peersPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Trading Recap: Will Entrada Therapeutics Inc benefit from rising consumer demandGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
Harmony Biosciences (NASDAQ:HRMY) and Entrada Therapeutics (NASDAQ:TRDA) Critical Review - Defense World
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Understanding the Setup: (TRDA) and Scalable Risk - Stock Traders Daily
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year HighTime to Buy? - MarketBeat
Aug Breakouts: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Gainers & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Volume: How does Entrada Therapeutics Inc compare to its peersJuly 2025 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (TRDA) CFO executes planned stock sale - Stock Titan
Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA - MarketBeat
HC Wainwright Has Optimistic Outlook of TRDA Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for TRDA Earnings - MarketBeat
Form 144: TRDA insider sales — Kory Wentworth sold 8,651 shares (TRDA) - Stock Titan
TRDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants - National Today
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
The Technical Signals Behind (TRDA) That Institutions Follow - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO) - The Globe and Mail
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
TRDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives - simplywall.st
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside - DirectorsTalk Interviews
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TRDAForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Entrada Therapeutics Q4 net loss and EPS beat expectations - TradingView
Earnings Summary: Entrada Therapeutics Q4 - Benzinga
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Entrada Therapeutics (NASDAQ: TRDA) maps DMD, DM1 and ocular drug pipeline - Stock Titan
Entrada Therapeutics (TRDA) swings to 2025 loss while advancing DMD pipeline - Stock Titan
DMD trials advance as Entrada extends cash runway to Q3 2027 - Stock Titan
Entrada Therapeutics : Corporate Presentation February 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
What analysts say about Entrada Therapeutics Inc. stockM&A Rumor & Long-Term Safe Investment Plans - mfd.ru
Entrada Therapeutics’ (TRDA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Potential Upside of 67.57% Could Attract Investors - DirectorsTalk Interviews
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):